Today: 28 June 2026
Browse Category

NYSE:GSK 20 December 2025 - 10 June 2026

Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly will acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company Inc. for up to $3.83 billion in cash, gaining vaccine programs for shingles, staph infections, and Epstein-Barr virus. Shares rose about 5% after news of the deals and broader coverage for Zepbound and Foundayo. Curevo shareholders may receive up to $1.5 billion, LimmaTech $780 million, and Vaccine Company $1.55 billion.
28 May 2026
···
GSK stock leaps to a 25-year high on new CEO outlook — what to watch at the London open

GSK stock leaps to a 25-year high on new CEO outlook — what to watch at the London open

GSK shares surged 6.9% Wednesday to a 25-year high after reporting 2025 sales of £32.7 billion and raising its 2026 outlook. The company projects 2026 revenue growth of 3%–5% and expects core profit and earnings per share to rise 7%–9%. Investors remain cautious about slower growth and looming patent expirations. London markets await Thursday’s open for further reaction.
5 February 2026
··
GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK shares closed down 0.2% at 1,801 pence in London Friday after China approved Trelegy Ellipta for uncontrolled asthma in adults. The expanded label gives GSK access to an estimated 46 million adults with asthma in China. Investors await GSK’s Q4 and full-year results, set for Feb. 4. The FTSE 100 slipped 0.07% on the day.
24 January 2026
·····
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open

GSK’s U.S.-listed shares fell 1.2% to $47.65 premarket after it agreed to buy RAPT Therapeutics for $2.2 billion, paying a 65% premium for rights to a mid-stage food allergy drug. The deal, led by new CEO Luke Miels, comes as GSK faces pressure to offset losses from expiring HIV drug patents. Pfizer will exit the ViiV Healthcare joint venture, with Shionogi raising its stake to 21.7%.
21 January 2026
···
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

AnaptysBio filed a motion to dismiss part of GSK’s claim in a Delaware court dispute over royalties from cancer drug Jemperli. The court is expected to hear the motion by early March, with trial set for July. GSK ADRs closed up 0.3% at $50.39 in New York; London shares slipped 0.26% to 1,886 pence. Investors await GSK’s Jan. 13 conference appearance and Feb. 4 results.
10 January 2026
····
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK’s U.S. ADR closed at $48.96 after the FDA approved its twice-yearly asthma drug Exdensur, but withheld approval for a related use. The company also reached a U.S. drug-pricing deal affecting its respiratory products and reported progress on vaccine expansion in Europe. London trading paused for holidays. Shingrix faces new competition.
26 December 2025
···
GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK disclosed a buyback of 232,912 shares on Dec. 19, 2025, at an average price of 1,807.58p, bringing total repurchases since late September to over 14.5 million shares. The company also reported director share purchases and reached a US drug pricing agreement. Shares traded near $48.59 Tuesday, little changed. Samsung Biologics agreed to buy a US facility from GSK for $280 million.
23 December 2025
·
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
1 2

Stock Market Today

  • Baidu Stock Valuation After Volatile Year: Is Current Price Attractive?
    June 28, 2026, 5:58 AM EDT. Baidu (NasdaqGS:BIDU) has returned 21% over the past year despite a 30.7% decline year-to-date amid shifting investor sentiment on Chinese tech and regulatory risks. The stock trades close to its intrinsic value at $102.81 based on a Discounted Cash Flow (DCF) analysis, just 1.4% above the current price, suggesting fair valuation. Baidu scores 2/6 on valuation checks, indicating mixed signals on undervaluation. Free cash flow estimates point to improvement by 2029, though recent figures showed losses. Price-to-sales ratio analysis also factors into assessing investor pricing against revenue. Overall, Baidu's stock price reflects the balance between growth prospects and regulatory concerns, warranting close monitoring for investors seeking opportunities in volatile Chinese tech stocks.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 6:07 AM EDT Baidu Stock Valuation After Volatile Year: Is Current Price Attractive? June 28, 2026, 5:58 AM EDT. Baidu (NasdaqGS:BIDU) has returned 21% over the past year despite a 30.7% decline year-to-date amid shifting investor sentiment on Chinese tech and regulatory risks. The stock trades close to its intrinsic value at $102.81 based on a Discounted Cash Flow (DCF) analysis, just 1.4% above the current price, suggesting fair valuation. Baidu scores 2/6 on valuation checks, indicating mixed signals on undervaluation. Free cash flow estimates point to improvement
Go toTop